Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -3.77% 12.75p 12.50p 13.00p 13.25p 12.75p 13.25p 414,369.00 10:05:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.6 -2.5 - 11.65

Synairgen Share Discussion Threads

Showing 601 to 622 of 625 messages
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
DateSubjectAuthorDiscuss
28/4/2017
14:03
If Woodford puts up any more cash - rather than cutting and running could well be in high coupon preference shares with blocking rights possibly similar to those used to further fund RM2 - but with all his problems with health development coys such as Allied Minds he might/should let them die.
pugugly
28/4/2017
13:19
I think the board needs to provide some more information. What were the preset criteria AZ used to assess the drug and was it able to meet them given the early halt to the trial? There's a big difference between bad data and too little data.Regardless, it's bad news. At a minimum, Synairgen has lost three years on the interferon, since any new partner will surely want a new P2. I agree with the comment above that it's now tainted and it'll be hard to find another partner, even if the science is still reasonably positive.
mirako
28/4/2017
10:57
MMS got this by the goolies people. They offloaded those 3.6m shs at 7p to punters above 13p. Don't leave much to the imagination what they are going to do now, compounding with the facts a fund raising will happen and high probability biggies will start cutting the holdings.
big bear billy
28/4/2017
08:20
Cash call at 6p, but they need to fast though. Sp is surely heading towards 10p now.
duck_and_dive
28/4/2017
07:14
That announcement yesterday morning was not entirely surprising. I think they will struggle to find another taker for the interferon program. They have enough cash to complete their LOXL2 commitments, but presumably not beyond. With a market cap of just £12, what next? Woodford will no doubt have a big say in the future direction, but I suspect a cash call will be involved somewhere along the line. Oh joy!
timbo003
27/4/2017
12:06
my old friend glencut, you're never far from bad news and shti stirring!
nakedsteve
27/4/2017
11:28
Is the 😼 Alive or 🙀 Die mmmmm! Any thoughts on tomorow🤔
glenkaz
27/4/2017
11:04
Careful Mr Glenkaz, there could be more II selling, they need money. Read the RNS, today intraday dead cat bounce is over I think.
big bear billy
27/4/2017
11:03
Really unfortunate for that sell. Right issue at 7p? They better be quick, otherwise could be begging bowl with Darwin, Henderson or Crede. What about more biggies running with their pants down here, in the background?
big bear billy
27/4/2017
10:24
13.5 sell 14.75 buy 👺👹 mm's taking the p/ss!! Gla! 😋
glenkaz
27/4/2017
10:02
It might have been Leonard Licht who held 3,700,000 throwing in the towel.
rosejs2
27/4/2017
10:00
Could rise to 15p-16p now.
big bear billy
27/4/2017
09:58
A 950K holding (worth yesterday) sold at 7p for 255K
big bear billy
27/4/2017
09:56
Deary me Someone got liquidated here. 3.6m @ 7.00p. very harsh.
big bear billy
27/4/2017
09:07
plenty of lumpy buying at 13.5p which was just about its previous low point in december.
ohisay
27/4/2017
08:09
Not at all good news today especially as they will need to do a fund raising at some point in the next few months.
ohisay
22/3/2017
14:57
Share price nearly back to where it was pre AZN announcement.....
wookie77
13/3/2017
22:37
Herewith a few notes from my phone conversation with RM of Friday afternoon (the Q&As are paraphrased, they are not verbatim): Q: Has there been some slippage on the timeline for an update on the Interferon study with Astra Zeneca? A: We may have previously stated Q1, we are now stating H1 and we are confident about that, although the timings are ultimately down to Astra Zeneca. Q: Can you tell us anything more about the lead compound, such as likely dose, PK properties, chemical structure? A: Most of that is confidential, it doesn’t have a name or number yet, it is a small molecule, it is not a peptide, preclinical data suggests it should be suitable for oral administration. Tox is ongoing, we will update when the necessary tox program to support a Phase I study is complete (later this year). Q: You have mentioned other indications for the LOXL2 program in addition to IPF such as liver, kidney and cardiac fibrosis. What about other more common fibrotic conditions such as Peyronie's disease and Dupuytren's contracture where there is a real unmet clinical need? These could be massive markets. A: Dupuytren's contracture has been mentioned a few times in meetings, but not Peyronie’s disease, we will make enquiries. * Dupuytren's contracture: https://en.wikipedia.org/wiki/Dupuytren%27s_contracture * Peyronie’s disease: https://en.wikipedia.org/wiki/Peyronie%27s_disease Q: Are Pharmaxis likely to develop just one molecule for all LOXL2 indications, or could it be multiple molecules? There may be commercial advantages for them to have different molecules for different indications as they could then have multiple partners, but this could mean SNG might be shut out of royalties for the additional indications. A: Our agreement covers all exploratory compounds in the LOXL2 program, so there is likely to be only one lead molecule. Pharmaxis may develop molecules which have some LOX2 activity but are predominantly specific for LOX, LOXL1, LOXL3 or LOXL4, such compounds would not necessarily be covered by the Synairgen agreement. LOXL2 is the main target for fibrosis of soft organs, but for structural tissue fibrosis the enzymes responsible may be other types of LOXL or LOX
timbo003
13/3/2017
17:59
Latest RNS Today.. Woodford has increased his holding by 125000 shares to 21,091,651..He now control's 23% of SNG share capital.
rosejs2
11/3/2017
15:21
Thanks Timbo - oddly enough I added 50% to my PXS holding week before last - whole fibrosis space there much undervalued IMV - CEO bought shares there 1st week December at around the current 28c price though I'd be surprised if it stayed there Monday..
ohisay
10/3/2017
23:18
That was really good news today: Efficacy demonstrated in several different preclinical models, the lead candidate is bioavailable following oral administration (in animal models) and tox looking good so far. There's a new interview with Richard Marsden here: http://www.proactiveinvestors.co.uk/companies/stocktube/7083/synairgen-s-chief-hails-exciting-ipf-data-from-loxl2-inhibitor-programme-7083.html I also had a chance to have a quick phone chat with RM late this afternoon which helped fill in a few gaps, I will write up a few notes on that and post them here sometime over the weekend.
timbo003
17/2/2017
09:35
Steve - If you want to see a real ramper at work look at these posts (especially on the 19th). http://uk.advfn.com/forum/search?q=whites123&index=posts&post_poster=on&offset=0 He's done exactly the same thing on iii under a different name - disorder. Give him a suitably wide berth in future.
ohisay
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170430 13:02:29